The estimated Net Worth of Kenneth F Buechler is at least 4.99 百万$ dollars as of 12 April 2024. Kenneth Buechler owns over 9,041 units of QuidelOrtho stock worth over 3,753,003$ and over the last 17 years he sold QDEL stock worth over 1,000,000$. In addition, he makes 240,055$ as Independent Chairman of the Board at QuidelOrtho.
Sign up
Kenneth Buechler QDEL stock SEC Form 4 insiders trading
Kenneth has made over 27 trades of the QuidelOrtho stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 9,041 units of QDEL stock worth 190,494$ on 12 April 2024.
The largest trade he's ever made was exercising 12,154 units of QuidelOrtho stock on 15 February 2018 worth over 197,503$. On average, Kenneth trades about 2,519 units every 89 days since 2007. As of 12 April 2024 he still owns at least 83,679 units of QuidelOrtho stock.
You can see the complete history of Kenneth Buechler stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kenneth Buechler biography
Dr. Kenneth F. Buechler serves as Independent Chairman of the Board of the Company. Dr. Buechler was previously the co-founder of and held various roles at Biosite Inc. from 1988 until its acquisition by Alere Inc. in 2007, including serving as a director and as President and Chief Scientific Officer, Senior Vice President, Research and Development, Vice President, Research and Director of Chemistry. Prior to co-founding Biosite, Dr. Buechler was a senior research scientist for the diagnostics research and development group at Hybritech Incorporated. Dr. Buechler recently served as a director of Sequenom Inc., a life sciences company until its acquisition in September 2016, Astute Medical Inc., a company that develops biomarkers for acute medical conditions until its acquisition in April 2018 and Edico Genome Inc., a DNA sequencing technology company until its acquisition in May 2018. Dr. Buechler received his Ph.D. in biochemistry and his bachelor’s degree in chemistry from Indiana University.
What is the salary of Kenneth Buechler?
As the Independent Chairman of the Board of QuidelOrtho, the total compensation of Kenneth Buechler at QuidelOrtho is 240,055$. There are 13 executives at QuidelOrtho getting paid more, with Douglas Bryant having the highest compensation of 4,168,770$.
How old is Kenneth Buechler?
Kenneth Buechler is 66, he's been the Independent Chairman of the Board of QuidelOrtho since 2015. There are 4 older and 23 younger executives at QuidelOrtho. The oldest executive at QuidelOrtho Corporation is Mary Polan, 76, who is the Independent Director.
Insiders trading at QuidelOrtho
Over the last 21 years, insiders at QuidelOrtho have traded over 509,235,797$ worth of QuidelOrtho stock and bought 304,015 units worth 10,385,234$ . The most active insiders traders include Jack W Schuler、Matthew Strobeck、Group Inc.Carlyle Holdings .... On average, QuidelOrtho executives and independent directors trade stock every 16 days with the average trade being worth of 1,246,606$. The most recent stock trade was executed by Group Inc.Carlyle Holdings ... on 9 August 2024, trading 74,134 units of QDEL stock currently worth 3,078,785$.
What does QuidelOrtho do?
QuidelOrtho Corporation is a major American manufacturer of diagnostic healthcare products that are sold worldwide.
What does QuidelOrtho's logo look like?
Complete history of Kenneth Buechler stock trades at QuidelOrtho
QuidelOrtho executives and stock owners
QuidelOrtho executives and other stock owners filed with the SEC include:
-
Douglas Bryant,
President, Chief Executive Officer, Director -
Douglas C. Bryant,
Pres, CEO & Director -
Randall Steward,
Chief Financial Officer -
Michael Abney,
Senior Vice President - Distribution -
Robert Bujarski,
Chief Operating Officer -
Ratan Borkar,
Senior Vice President - International Commercial Operations -
Werner Kroll,
Senior Vice President - R&D -
Edward Russell,
Senior Vice President - Business Development -
Robert J. Bujarski,
Chief Operating Officer -
Randall J. Steward,
Chief Financial Officer -
Dr. Werner Kroll,
Sr. VP of R&D -
Ratan S. Borkar,
Sr. VP of International Commercial Operations -
Robert J. Bujarski J.D.,
Pres & COO -
Kenneth Buechler,
Independent Chairman of the Board -
Edward Michael,
Independent Director -
Ken Widder,
Independent Director -
Charles Slacik,
Independent Director -
Matthew Strobeck,
Independent Director -
Mary Polan,
Independent Director -
Kathy Ordonez,
Independent Director -
Ruben Argueta,
Director - Investor Relations -
Ann Rhoads,
Director -
Karen Gibson,
Senior Vice President, Information Systems and Business Transformation -
Dr. Chockalingam Palaniappan Ph.D.,
Chief Innovation Officer -
Patrick E. Klein,
Chief Admin. Officer -
Louise Brandy,
Chief Information Officer -
Rhys de Callier,
VP of Strategy & Portfolio Management -
Dr. Johannes Kehle,
Pres of AnDiaTec Division -
Phillip S. Askim,
VP, Associate Gen. Counsel & Sec. -
Michael S. Iskra,
Chief Commercial Officer -
Joseph M. Busky CPA,
Chief Financial Officer -
Karen C. Gibson,
Sr. VP of Digital Health Bus. Unit -
Edward Keith Russell,
Sr. VP of Bus. Devel. -
Michael Donald Abney Jr.,
Sr. VP of North American Sales & Distribution -
Michelle A. Hodges,
Sr. VP & Gen. Counsel -
Group Inc.Carlyle Holdings ...,
-
Thomas D Brown,
Director -
Rodney F Dammeyer,
Director -
John Tamerius,
Sr. VP - Clinical/Reg Affairs -
Patrick Klein,
Chief Administrative Officer -
Louise Brandy,
SVP, Chief Information Officer -
Tamara A. Ranalli,
SVP, Molecular Bus. Unit -
Mark W Smits,
SVP-Commercial Operations -
Mark Pulido,
Director -
John Matthew Radak,
Chief Financial Officer -
Timothy Todd Stenzel,
Chief Science Officer -
Scot M Mc Leod,
Sr. VP - Operations -
Caren L Mason,
President and CEO -
Jack W Schuler,
Director -
Thomas James Foley,
Chief Technical Officer -
David R. Scholl,
Senior Vice President -
Richard C Iii Tarbox,
Sr. VP - Corporate Development -
Matthew T Heindel,
Sr. VP - Global Sales & Mrktg -
Douglas S Harrington,
Director -
Faye Wattleton,
Director -
Mark Paiz,
Senior Vice President -
Thomas A Glaze,
Director -
Paul E Landers,
Sr. V.P., CFO and Secretary -
S Wayne Kay,
President & CEO -
William J. Ferenczy,
SVP, Cardio/Metabolic Unit -
Michael S. Iskra,
EVP & CCO -
Christopher M Smith,
Director -
Joseph D Jr. Wilkins,
-
Evelyn S Dilsaver,
-
Joseph M Busky,
Chief Financial Officer -
James Prutow,
-
Michelle A. Hodges,
SVP, General Counsel